GlassScriptPhysician profile
Duc Hong Quach
NPI 1922567379
$3,648.07
in general payments reported to CMS, 2019-2025
20 companies · $2,911 in 2025
The $2,911 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $330 · 2023: $27.42 · 2024: $380 · 2025: $2,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151 · Travel and Lodging: $1,154 · Education: $13.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.67 |
| Travel and Lodging | $1,153.92 |
| Education | $13.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $1,305.33 | 2025 | Renal - Chronic |
| Astrazeneca Pharmaceuticals LP | $429.32 | 2022-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $365.14 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $233.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.26 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $158.89 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $149.12 | 2024-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $141.58 | 2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $140.88 | 2024-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $139.75 | 2025 | Veltassa |
| Travere Therapeutics, INC. | $64.33 | 2025 | Filspari |
| Lilly USA, LLC | $60.91 | 2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $53.48 | 2023-2025 | |
| Medtronic, INC. | $51.05 | 2025 | Symplicity G3 |
| Amgen INC. | $42.80 | 2025 | Tavneos, Krystexxa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.48 | 2024 | Acthar |
| Novo Nordisk INC | $25.46 | 2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $24.24 | 2025 | Lupkynis |
| Akebia Therapeutics INC | $20.60 | 2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $18.19 | 2025 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duc Quach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.